| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
3,704 |
4,538 |
27,327 |
202,315 |
| Total Sell Value |
$438,449 |
$537,921 |
$3,641,323 |
$29,586,917 |
| Total People Sold |
1 |
3 |
13 |
19 |
| Total Sell Transactions |
2 |
4 |
21 |
79 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-08-01 |
4 |
AS |
$153.48 |
$1,126,645 |
D/D |
(7,301) |
354,311 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-08-01 |
4 |
OE |
$46.83 |
$455,087 |
D/D |
9,700 |
361,612 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-07-12 |
4 |
AS |
$155.00 |
$82,460 |
D/D |
(532) |
11,309 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-07-12 |
4 |
OE |
$109.45 |
$58,227 |
D/D |
532 |
11,841 |
|
- |
|
| Tovey Christopher J. |
EVP, COO & Managing Director E |
• – – |
2022-07-05 |
4 |
AS |
$160.00 |
$833,440 |
D/D |
(5,209) |
14,663 |
|
- |
|
| Tovey Christopher J. |
EVP, COO & Managing Director E |
• – – |
2022-07-05 |
4 |
OE |
$0.02 |
$81 |
D/D |
4,032 |
19,872 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-07-05 |
4 |
AS |
$156.65 |
$1,380,146 |
D/D |
(8,775) |
351,912 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-07-05 |
4 |
OE |
$46.83 |
$454,251 |
D/D |
9,700 |
360,687 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-06-27 |
4 |
AS |
$155.00 |
$1,318,740 |
D/D |
(8,508) |
11,309 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-06-27 |
4 |
OE |
$109.45 |
$931,201 |
D/D |
8,508 |
19,817 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-06-08 |
4 |
AS |
$155.00 |
$1,315,485 |
D/D |
(8,487) |
11,309 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-06-08 |
4 |
OE |
$109.45 |
$638,641 |
D/D |
5,835 |
19,796 |
|
- |
|
| Sablich Kim |
EVP & GM, North America |
• – – |
2022-06-07 |
4 |
AS |
$148.21 |
$368,714 |
D/D |
(2,441) |
24,754 |
|
- |
|
| Sablich Kim |
EVP & GM, North America |
• – – |
2022-06-06 |
4 |
AS |
$152.15 |
$211,184 |
D/D |
(1,388) |
27,195 |
|
- |
|
| Sablich Kim |
EVP & GM, North America |
• – – |
2022-06-06 |
4 |
D |
$149.25 |
$262,531 |
D/D |
(1,759) |
28,583 |
|
- |
|
| Iannone Robert |
EVP, Global Head of R&D |
• – – |
2022-06-06 |
4 |
D |
$149.25 |
$193,279 |
D/D |
(1,295) |
38,109 |
|
- |
|
| Patil Neena M |
Chief Legal Officer (CLO) |
• – – |
2022-06-06 |
4 |
AS |
$152.15 |
$152,150 |
D/D |
(1,000) |
31,600 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2022-06-02 |
4 |
S |
$150.26 |
$19,684 |
D/D |
(131) |
6,234 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-06-02 |
4 |
AS |
$150.00 |
$150,000 |
D/D |
(1,000) |
350,987 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-06-01 |
4 |
AS |
$145.42 |
$934,369 |
D/D |
(6,362) |
351,987 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-06-01 |
4 |
OE |
$46.83 |
$454,251 |
D/D |
9,700 |
358,349 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2022-05-11 |
4 |
S |
$147.51 |
$106,505 |
D/D |
(722) |
6,234 |
|
- |
|
| Patil Neena M |
Chief Legal Officer (CLO) |
• – – |
2022-05-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
161 |
32,516 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2022-05-10 |
4 |
S |
$144.18 |
$39,361 |
D/D |
(273) |
6,956 |
|
- |
|
| Oriordan Anne |
Director |
– • – |
2022-05-09 |
4 |
S |
$148.92 |
$69,411 |
D/D |
(466) |
9,245 |
|
- |
|
881 Records found
|
|
Page 7 of 36 |
|
|
0.37 (0.34%) 
